Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions: SR604, Placebo; Drug
Lead sponsor: Equilibra Bioscience LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Multiple Myeloma
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 24
States / cities: Scottsdale, Arizona • Berkeley, California • Duarte, California + 19 more

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: X-Linked Retinitis Pigmentosa
Interventions: BIIB112; Biological
Lead sponsor: Biogen; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more

Conditions: Dermatomyositis
Interventions: Ravulizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more

Conditions: Post-Bariatric Hypoglycemia
Interventions: Use of Continuous Glucose Monitor (CGM), Use of "Cardea Solo" monitoring; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Menopausal, Dementia
Interventions: PERI-MIND; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 58 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib (Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more

Conditions: Advanced Solid Cancers
Interventions: BMS-986301, Nivolumab, Ipilimumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Sickle Cell Disease
Interventions: Prasugrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Acute Myeloid Leukemia
Interventions: Gilteritinib, Idarubicin, Cytarabine, Daunorubicin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 7 more

Conditions: Cardiovascular Diseases, Hyperlipidemias
Interventions: Lipid Challenge, Glucose Challenge, Mixed Meal Challenge; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Spinal Surgery for Lumbar Spinal Stenosis (LSS)
Interventions: Wrist based activity tracker wear, Basic Study Activities, Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions: Vimseltinib, Placebo; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 11
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Pain Measurement
Interventions: Qualitative Interview; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cutaneous Lupus, Systemic Lupus Erythematosus
Interventions: Tofacitinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Cincinnati, Ohio • Cleveland, Ohio

Conditions: PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions: Beef+; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 11 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Neoplasm Metastasis
Interventions: Drug Cocktail, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more

Conditions: Opioid Use Disorder
Interventions: CVL-354, [11C]-LY2795050, [11C]-carfentanil; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions: Tofersen, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more

Conditions: Post-cardiac Surgery, Hyperlactatemia
Interventions: Pyruvate levels; Other
Lead sponsor: University of Florida; Other
Eligibility: Up to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: Colin D. Weekes, M.D., PhD; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk

Natural History Study for DNA Repair Disorders

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

The Mixed Meal Challenge Study

Activity Post Spinal Surgery Engagement Trial

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

COA-APTIC Clinician Concept Elicitation Study

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

Lactate Acidosis in Postoperative Hearts

FOLFIRINOX + NIS793 in Pancreatic Cancer